Shopping Cart 0
Cart Subtotal
USD 0

Ipsen SA (IPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA (IPN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13

Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ipsen SA, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18

Ipsen Acquires Oncology Assets from Merrimack Pharma 20

Venture Financing 22

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24

Rhythm Pharma Raises USD 33 Million In Series B Financing 26

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 30

Partnerships 31

Arix Bioscience and Ipsen Enter into Co-Development Agreement 31

Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32

Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33

Ipsen Partners with Oncodesign 34

Ipsen Enters into Research Agreement with PeptiMimesis 35

Ipsen Enters into Research Agreement with Aepodia 36

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37

Ipsen Enters into Research Agreement with Interprotein 38

Ipsen and EpiVax Enter into Partnership 39

Ipsen Enters into Research Agreement with Hannover Medical School 40

Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 41

Ipsen Extends Research Agreement with Salk Institute for Biological Studies 42

Ipsen Extends Distribution Agreement with Galderma for Dysport 43

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 45

Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 46

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 47

PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 48

PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49

Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 50

Ipsen Extends Distribution Agreement With Galderma For Dysport 52

Oncodesign Enters into Research Agreement with Ipsen 53

Licensing Agreements 54

Ipsen Enters into Licensing Agreement with MD Anderson 54

Merrimack Pharma Enters into Licensing Agreement with Ipsen 55

Ipsen Amends Licensing Agreement with Exelixis 56

Ipsen Enters into Licensing Agreement with 3B Pharma 57

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58

Lexicon Pharma Expands Licensing Agreement with Ipsen 59

Otonomy Enters into Licensing Agreement with Ipsen 60

Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61

Ipsen Enters into Licensing Agreement with Probi 63

Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64

Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65

Equity Offering 66

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66

Debt Offering 68

Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68

Asset Transactions 69

Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69

Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For USD 300 Million 71

Acquisition 73

Ipsen to Acquire Equity Stake in Akkadeas Pharma 73

Ipsen Acquires Canbex Therapeutics 74

Ipsen Acquires OctreoPharm Sciences for USD57 Million 75

Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 76

Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78

Ipsen SA-Key Competitors 79

Ipsen SA-Key Employees 80

Ipsen SA-Locations And Subsidiaries 82

Head Office 82

Other Locations & Subsidiaries 82

Affiliate 84

Joint Venture 84

Recent Developments 85

Financial Announcements 85

Oct 25, 2018: Ipsen delivers strong sales growth of 20.2%1 for the third quarter of 2018 and confirms full year guidance 85

Jul 26, 2018: Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018 87

Feb 15, 2018: Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018 88

Jul 27, 2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017 90

Apr 27, 2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1 98

Feb 23, 2017: Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017 101

Corporate Communications 109

Sep 27, 2018: Ipsen names Dr. Yan Moore as Senior Vice President, Head of Oncology therapeutic area; and Dr. Alexander McEwan, FRCPC, as Vice President, Head of Radiopharmaceuticals 109

Mar 13, 2018: Ipsen Announces Executive Leadership Appointments 110

Jan 26, 2018: Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer 111

Jan 12, 2018: Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America 112

Apr 14, 2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer 113

Feb 06, 2017: Ipsen announces appointment of Dr. Sotirios G. Stergiopoulos as Head of Global Medical Affairs 114

Jan 20, 2017: Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises 115

Product News 116

09/18/2017: U.S. FDA Approves New Indication for Ipsen's Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome 116

09/04/2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress 117

07/21/2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 118

07/03/2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors 119

06/01/2017: Ipsen To Present New Data of Lanreotide at ASCO 120

06/01/2017: Ipsen To Present New Data on Investigational Compound Lu-OPS201 at ASCO 121

05/01/2018: Novel Theranostic Approach for Treating Pancreatic Cancer Patients Shows Promise 122

04/17/2017: Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research 123

03/09/2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 124

03/09/2017: Ipsen announces presentation on the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 126

02/13/2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs) 127

01/15/2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018 128

Product Approvals 129

Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 129

Mar 28, 2017: NICE says pancreatic cancer drug is not cost effective for routine NHS use 131

Mar 13, 2017: Shire's Onivyde Rejects For Use Within NHS Scotland 132

Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC 133

Clinical Trials 134

Jun 01, 2017: Ipsen Announces Presentation of New Data on Irinotecan at ASCO 134

May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis 135

Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies 136

Mar 27, 2017: Merrimack to Present Data on MM-398 at the 2017 American Association for Cancer Research Annual Meeting 138

Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis 139

Other Significant Developments 141

Oct 04, 2018: Ipsen Joins Biotechnology Innovation Organization (BIO) to advance growth and innovation 141

Jul 10, 2018: Ipsen welcomes Frederique Vidal, Minister of Higher Education, Research and Innovation, at its new development center in Dreux 142

Jun 07, 2018: Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts 143

Appendix 144

Methodology 144

About GlobalData 144

Contact Us 144

Disclaimer 144


List Of Figure

List of Figures

Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Ipsen SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ipsen SA, Deals By Therapy Area, 2012 to YTD 2018 11

Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13

Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18

Ipsen Acquires Oncology Assets from Merrimack Pharma 20

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24

Rhythm Pharma Raises USD 33 Million In Series B Financing 26

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 30

Arix Bioscience and Ipsen Enter into Co-Development Agreement 31

Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32

Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33

Ipsen Partners with Oncodesign 34

Ipsen Enters into Research Agreement with PeptiMimesis 35

Ipsen Enters into Research Agreement with Aepodia 36

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37

Ipsen Enters into Research Agreement with Interprotein 38

Ipsen and EpiVax Enter into Partnership 39

Ipsen Enters into Research Agreement with Hannover Medical School 40

Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 41

Ipsen Extends Research Agreement with Salk Institute for Biological Studies 42

Ipsen Extends Distribution Agreement with Galderma for Dysport 43

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 45

Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 46

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 47

PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 48

PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49

Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 50

Ipsen Extends Distribution Agreement With Galderma For Dysport 52

Oncodesign Enters into Research Agreement with Ipsen 53

Ipsen Enters into Licensing Agreement with MD Anderson 54

Merrimack Pharma Enters into Licensing Agreement with Ipsen 55

Ipsen Amends Licensing Agreement with Exelixis 56

Ipsen Enters into Licensing Agreement with 3B Pharma 57

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58

Lexicon Pharma Expands Licensing Agreement with Ipsen 59

Otonomy Enters into Licensing Agreement with Ipsen 60

Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61

Ipsen Enters into Licensing Agreement with Probi 63

Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64

Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66

Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68

Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69

Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For USD 300 Million 71

Ipsen to Acquire Equity Stake in Akkadeas Pharma 73

Ipsen Acquires Canbex Therapeutics 74

Ipsen Acquires OctreoPharm Sciences for USD57 Million 75

Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 76

Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78

Ipsen SA, Key Competitors 79

Ipsen SA, Key Employees 80

Ipsen SA, Subsidiaries 82

Ipsen SA, Affiliate 84

Ipsen SA, Joint Venture 84

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ipsen SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA (IPN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13

Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ipsen SA, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18

Ipsen Acquires Oncology Assets from Merrimack Pharma 20

Venture Financing 22

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24

Rhythm Pharma Raises USD 33 Million In Series B Financing 26

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 30

Partnerships 31

Arix Bioscience and Ipsen Enter into Co-Development Agreement 31

Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32

Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33

Ipsen Partners with Oncodesign 34

Ipsen Enters into Research Agreement with PeptiMimesis 35

Ipsen Enters into Research Agreement with Aepodia 36

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37

Ipsen Enters into Research Agreement with Interprotein 38

Ipsen and EpiVax Enter into Partnership 39

Ipsen Enters into Research Agreement with Hannover Medical School 40

Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 41

Ipsen Extends Research Agreement with Salk Institute for Biological Studies 42

Ipsen Extends Distribution Agreement with Galderma for Dysport 43

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 45

Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 46

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 47

PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 48

PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49

Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 50

Ipsen Extends Distribution Agreement With Galderma For Dysport 52

Oncodesign Enters into Research Agreement with Ipsen 53

Licensing Agreements 54

Ipsen Enters into Licensing Agreement with MD Anderson 54

Merrimack Pharma Enters into Licensing Agreement with Ipsen 55

Ipsen Amends Licensing Agreement with Exelixis 56

Ipsen Enters into Licensing Agreement with 3B Pharma 57

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58

Lexicon Pharma Expands Licensing Agreement with Ipsen 59

Otonomy Enters into Licensing Agreement with Ipsen 60

Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61

Ipsen Enters into Licensing Agreement with Probi 63

Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64

Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65

Equity Offering 66

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66

Debt Offering 68

Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68

Asset Transactions 69

Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69

Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For USD 300 Million 71

Acquisition 73

Ipsen to Acquire Equity Stake in Akkadeas Pharma 73

Ipsen Acquires Canbex Therapeutics 74

Ipsen Acquires OctreoPharm Sciences for USD57 Million 75

Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 76

Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78

Ipsen SA-Key Competitors 79

Ipsen SA-Key Employees 80

Ipsen SA-Locations And Subsidiaries 82

Head Office 82

Other Locations & Subsidiaries 82

Affiliate 84

Joint Venture 84

Recent Developments 85

Financial Announcements 85

Oct 25, 2018: Ipsen delivers strong sales growth of 20.2%1 for the third quarter of 2018 and confirms full year guidance 85

Jul 26, 2018: Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018 87

Feb 15, 2018: Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018 88

Jul 27, 2017: Ipsen Delivers Strong Sales Growth of 18.8% in the First Half of 2017 and Upgrades Its Guidance for Full Year 2017 90

Apr 27, 2017: Ipsen Reports Strong First Quarter 2017 Sales Growth of 19,1%1 98

Feb 23, 2017: Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017 101

Corporate Communications 109

Sep 27, 2018: Ipsen names Dr. Yan Moore as Senior Vice President, Head of Oncology therapeutic area; and Dr. Alexander McEwan, FRCPC, as Vice President, Head of Radiopharmaceuticals 109

Mar 13, 2018: Ipsen Announces Executive Leadership Appointments 110

Jan 26, 2018: Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer 111

Jan 12, 2018: Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America 112

Apr 14, 2017: Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer 113

Feb 06, 2017: Ipsen announces appointment of Dr. Sotirios G. Stergiopoulos as Head of Global Medical Affairs 114

Jan 20, 2017: Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises 115

Product News 116

09/18/2017: U.S. FDA Approves New Indication for Ipsen's Somatuline Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome 116

09/04/2017: Ipsen To Present Data on Somatuline at European Society of Medical Oncology congress 117

07/21/2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 118

07/03/2017: Somatuline Autogel 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors 119

06/01/2017: Ipsen To Present New Data of Lanreotide at ASCO 120

06/01/2017: Ipsen To Present New Data on Investigational Compound Lu-OPS201 at ASCO 121

05/01/2018: Novel Theranostic Approach for Treating Pancreatic Cancer Patients Shows Promise 122

04/17/2017: Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research 123

03/09/2017: Ipsen announces data presentation on lanreotide (Somatuline Autogel) at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 124

03/09/2017: Ipsen announces presentation on the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference 126

02/13/2018: Health Canada approves Ipsen Somatuline Autogel for the treatment of carcinoid syndrome in adult patients with neuroendocrine tumours (NETs) 127

01/15/2018: Ipsen To Present Abstracts On lanreotide ASCO Gastrointestinal Symposium 2018 128

Product Approvals 129

Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture 129

Mar 28, 2017: NICE says pancreatic cancer drug is not cost effective for routine NHS use 131

Mar 13, 2017: Shire's Onivyde Rejects For Use Within NHS Scotland 132

Mar 10, 2017: Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC 133

Clinical Trials 134

Jun 01, 2017: Ipsen Announces Presentation of New Data on Irinotecan at ASCO 134

May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis 135

Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies 136

Mar 27, 2017: Merrimack to Present Data on MM-398 at the 2017 American Association for Cancer Research Annual Meeting 138

Feb 01, 2017: Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis 139

Other Significant Developments 141

Oct 04, 2018: Ipsen Joins Biotechnology Innovation Organization (BIO) to advance growth and innovation 141

Jul 10, 2018: Ipsen welcomes Frederique Vidal, Minister of Higher Education, Research and Innovation, at its new development center in Dreux 142

Jun 07, 2018: Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts 143

Appendix 144

Methodology 144

About GlobalData 144

Contact Us 144

Disclaimer 144


List Of Figure

List of Figures

Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Ipsen SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Ipsen SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Ipsen SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Ipsen SA, Deals By Therapy Area, 2012 to YTD 2018 11

Ipsen SA, Medical Devices Deals, 2012 to YTD 2018 13

Ipsen SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Ipsen Acquires Healthcare Portfolio from Sanofi for USD88.3 Million 18

Ipsen Acquires Oncology Assets from Merrimack Pharma 20

Rhythm Pharma Raises USD41 Million in Mezzanine Financing 22

Rhythm Metabolic Raises USD40 Million in Series A Financing Round 24

Rhythm Pharma Raises USD 33 Million In Series B Financing 26

Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 28

Rhythm Pharma Raises USD 9.5 Million In Venture Financing 30

Arix Bioscience and Ipsen Enter into Co-Development Agreement 31

Ipsen Enters into Co-Promotion Agreement with Saol Therapeutics 32

Ipsen Enters into Research Agreement with Institute of Molecular and Cell Biology 33

Ipsen Partners with Oncodesign 34

Ipsen Enters into Research Agreement with PeptiMimesis 35

Ipsen Enters into Research Agreement with Aepodia 36

Galderma Enters into Distribution Agreement with Ipsen for Dysport in Asia-Pacific 37

Ipsen Enters into Research Agreement with Interprotein 38

Ipsen and EpiVax Enter into Partnership 39

Ipsen Enters into Research Agreement with Hannover Medical School 40

Ipsen and CNRS Enter into Agreement with CEA and University of Rennes 41

Ipsen Extends Research Agreement with Salk Institute for Biological Studies 42

Ipsen Extends Distribution Agreement with Galderma for Dysport 43

GW Pharma Enters Into Distribution Agreement With Ipsen For Sativex 45

Ipsen And Mayoly Spindler Enter Into Cross-Promotion Agreement For Primary Care Activities In France 46

Ipsen Enters Into Research Agreement With Harvard Medical School To Discover Botulinum Toxins 47

PeptiDream Expands Co-Development Agreement With Ipsen For Peptide Drugs 48

PeptiDream Enters Into Research Agreement With Ipsen To Discover Therapeutic Peptides 49

Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 50

Ipsen Extends Distribution Agreement With Galderma For Dysport 52

Oncodesign Enters into Research Agreement with Ipsen 53

Ipsen Enters into Licensing Agreement with MD Anderson 54

Merrimack Pharma Enters into Licensing Agreement with Ipsen 55

Ipsen Amends Licensing Agreement with Exelixis 56

Ipsen Enters into Licensing Agreement with 3B Pharma 57

Ipsen Enters into Licensing Agreement with Telesta Therapeutics 58

Lexicon Pharma Expands Licensing Agreement with Ipsen 59

Otonomy Enters into Licensing Agreement with Ipsen 60

Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 61

Ipsen Enters into Licensing Agreement with Probi 63

Daewoong Enters Into Licensing Agreement With Ipsen Tianjin For Smecta Technology 64

Ipsen Enters Into Licensing Agreement With Inspiration Biopharma For IB1001 and OBI-1 65

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 66

Ipsen Raises USD341 Million in Public Offering of 1.875% Notes Due 2023 68

Baxter International Completes Acquisition Of Rights To OBI- 1 And Related Assets From Ipsen And Inspiration Biopharma For USD700 Million 69

Cangene Completes Acquisition Of Rights To Hemophilia Products From Ipsen And Inspiration For USD 300 Million 71

Ipsen to Acquire Equity Stake in Akkadeas Pharma 73

Ipsen Acquires Canbex Therapeutics 74

Ipsen Acquires OctreoPharm Sciences for USD57 Million 75

Ipsen Acquires Syntaxin, Life Sciences Company, For USD206 Million 76

Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 78

Ipsen SA, Key Competitors 79

Ipsen SA, Key Employees 80

Ipsen SA, Subsidiaries 82

Ipsen SA, Affiliate 84

Ipsen SA, Joint Venture 84

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ipsen SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.